دورية أكاديمية
The discrete roles of individual FOXO transcription factor family members in B-cell malignancies.
| العنوان: | The discrete roles of individual FOXO transcription factor family members in B-cell malignancies. |
|---|---|
| المؤلفون: | Lees J; Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Hay J; Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Moles MW; Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Michie AM; Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 May 18; Vol. 14, pp. 1179101. Date of Electronic Publication: 2023 May 18 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Forkhead Transcription Factors*/genetics , Forkhead Transcription Factors*/metabolism , Neoplasms*/pathology, Humans ; Gene Expression Regulation ; Signal Transduction ; Cell Differentiation |
| مستخلص: | Forkhead box (FOX) class O (FOXO) proteins are a dynamic family of transcription factors composed of four family members: FOXO1, FOXO3, FOXO4 and FOXO6. As context-dependent transcriptional activators and repressors, the FOXO family regulates diverse cellular processes including cell cycle arrest, apoptosis, metabolism, longevity and cell fate determination. A central pathway responsible for negative regulation of FOXO activity is the phosphatidylinositol-3-kinase (PI3K)-AKT signalling pathway, enabling cell survival and proliferation. FOXO family members can be further regulated by distinct kinases, both positively (e.g., JNK, AMPK) and negatively (e.g., ERK-MAPK, CDK2), with additional post-translational modifications further impacting on FOXO activity. Evidence has suggested that FOXOs behave as ' bona fide ' tumour suppressors, through transcriptional programmes regulating several cellular behaviours including cell cycle arrest and apoptosis. However, an alternative paradigm has emerged which indicates that FOXOs operate as mediators of cellular homeostasis and/or resistance in both 'normal' and pathophysiological scenarios. Distinct FOXO family members fulfil discrete roles during normal B cell maturation and function, and it is now clear that FOXOs are aberrantly expressed and mutated in discrete B-cell malignancies. While active FOXO function is generally associated with disease suppression in chronic lymphocytic leukemia for example, FOXO expression is associated with disease progression in diffuse large B cell lymphoma, an observation also seen in other cancers. The opposing functions of the FOXO family drives the debate about the circumstances in which FOXOs favour or hinder disease progression, and whether targeting FOXO-mediated processes would be effective in the treatment of B-cell malignancies. Here, we discuss the disparate roles of FOXO family members in B lineage cells, the regulatory events that influence FOXO function focusing mainly on post-translational modifications, and consider the potential for future development of therapies that target FOXO activity. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Lees, Hay, Moles and Michie.) |
| References: | FEBS J. 2014 Oct;281(19):4421-38. (PMID: 25065674) Semin Cancer Biol. 2018 Jun;50:90-100. (PMID: 29175105) Mediterr J Hematol Infect Dis. 2020 Nov 01;12(1):e2020073. (PMID: 33194147) J Clin Invest. 2021 Jan 4;131(1):. (PMID: 33393494) Nat Med. 2018 May;24(5):679-690. (PMID: 29713087) Immunity. 2015 Dec 15;43(6):1064-74. (PMID: 26620759) PLoS One. 2015 Mar 25;10(3):e0121474. (PMID: 25806826) Blood. 2018 Apr 5;131(14):1556-1567. (PMID: 29439954) Immunity. 2021 Aug 10;54(8):1807-1824.e14. (PMID: 34380064) Blood. 2018 May 24;131(21):2307-2319. (PMID: 29666115) Cell. 2012 Apr 13;149(2):274-93. (PMID: 22500797) Aging (Albany NY). 2012 Jul;4(7):462-79. (PMID: 22820736) Blood. 2011 Oct 13;118(15):4174-8. (PMID: 21856866) Life Sci Alliance. 2019 Nov 25;2(6):. (PMID: 31767615) Nature. 2010 Feb 4;463(7281):676-80. (PMID: 20130650) Sci Rep. 2022 Jan 25;12(1):1309. (PMID: 35079069) Nat Immunol. 2008 Dec;9(12):1388-98. (PMID: 18978794) Lancet Oncol. 2015 Sep;16(9):1111-1122. (PMID: 26256760) Nat Immunol. 2010 Jul;11(7):635-43. (PMID: 20543837) J Immunol. 2007 Jan 15;178(2):740-7. (PMID: 17202334) Cancer Sci. 2019 Dec;110(12):3695-3707. (PMID: 31571328) Structure. 2008 Sep 10;16(9):1407-16. (PMID: 18786403) Biochem Pharmacol. 2018 Jan;147:93-103. (PMID: 29155058) Cell. 2007 Jan 26;128(2):309-23. (PMID: 17254969) Stem Cells. 2014 Sep;32(9):2324-37. (PMID: 24806995) Immunity. 2014 Oct 16;41(4):529-42. (PMID: 25367570) Cancer Metastasis Rev. 2020 Sep;39(3):681-709. (PMID: 32372224) Nat Rev Clin Oncol. 2015 Jun;12(6):344-57. (PMID: 25781572) J Biol Chem. 2009 Aug 28;284(35):23204-16. (PMID: 19574223) Science. 2004 Mar 26;303(5666):2011-5. (PMID: 14976264) N Engl J Med. 2002 Jun 20;346(25):1937-47. (PMID: 12075054) Biochemistry. 2005 Aug 30;44(34):11608-17. (PMID: 16114898) Blood. 2018 Dec 20;132(25):2670-2683. (PMID: 30333121) Cell. 2011 Sep 2;146(5):697-708. (PMID: 21884932) Cell. 2007 Aug 10;130(3):440-55. (PMID: 17693255) Nat Rev Cancer. 2007 Aug;7(8):585-98. (PMID: 17646864) Clin Transl Oncol. 2013 Jan;15(1):3-8. (PMID: 22911550) Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2975-80. (PMID: 14978268) Nat Genet. 1993 Nov;5(3):230-5. (PMID: 8275086) J Exp Med. 2010 Jun 7;207(6):1209-21. (PMID: 20498019) Cancer Lett. 2021 Apr 10;503:197-212. (PMID: 33493586) Scientifica (Cairo). 2014;2014:208928. (PMID: 25101192) Oncogene. 2008 Apr 7;27(16):2312-9. (PMID: 18391973) Annu Rev Immunol. 2022 Apr 26;40:413-442. (PMID: 35113731) Biochem J. 2005 Nov 1;391(Pt 3):623-9. (PMID: 15987244) Cell. 2009 Oct 30;139(3):573-86. (PMID: 19879843) Cancer Res. 2009 Aug 15;69(16):6546-55. (PMID: 19654305) Cancers (Basel). 2019 Sep 25;11(10):. (PMID: 31557894) Oncogene. 2008 Apr 7;27(16):2276-88. (PMID: 18391970) Curr Top Dev Biol. 2018;127:165-192. (PMID: 29433737) Blood. 2019 Aug 8;134(6):534-547. (PMID: 31010847) Leukemia. 2019 Feb;33(2):287-298. (PMID: 30555163) Cell Death Dis. 2016 Jan 14;6:e2046. (PMID: 26764572) JCO Precis Oncol. 2017 Jul;2017:. (PMID: 28890946) Science. 2006 Oct 13;314(5797):294-7. (PMID: 17038621) Cell. 1999 Mar 19;96(6):857-68. (PMID: 10102273) Immunity. 2019 Aug 20;51(2):337-350.e7. (PMID: 31375460) Cell. 2007 Jan 26;128(2):325-39. (PMID: 17254970) Nat Immunol. 2006 May;7(5):489-97. (PMID: 16582912) Blood. 1997 Nov 1;90(9):3714-9. (PMID: 9345057) Oncogene. 2014 Jan 16;33(3):316-25. (PMID: 23318440) Nat Immunol. 2012 Jan 22;13(3):300-7. (PMID: 22267219) Semin Cancer Biol. 2018 Jun;50:65-76. (PMID: 29309929) Nat Med. 2017 Jun;23(6):703-713. (PMID: 28481359) J Clin Invest. 2001 Nov;108(9):1359-67. (PMID: 11696581) Leuk Lymphoma. 2008 Oct;49(10):1945-53. (PMID: 18728964) Nat Commun. 2021 Jun 10;12(1):3526. (PMID: 34112805) Front Immunol. 2022 May 04;13:880668. (PMID: 35603175) Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17402-7. (PMID: 21972416) J Allergy Clin Immunol. 2013 Apr;131(4):959-71. (PMID: 23465663) J Clin Invest. 2022 Dec 15;132(24):. (PMID: 36282572) Curr Opin Immunol. 2011 Apr;23(2):178-83. (PMID: 21277760) Cell Cycle. 2014;13(5):807-19. (PMID: 24407358) Blood. 2010 Mar 25;115(12):2430-40. (PMID: 20086250) Blood. 2021 Sep 2;138(9):758-772. (PMID: 33786575) Cell. 2000 Sep 1;102(5):553-63. (PMID: 11007474) Oncogenesis. 2022 Jan 10;11(1):1. (PMID: 35013097) Br J Haematol. 2012 Feb;156(3):334-45. (PMID: 22107151) Blood. 2004 Aug 1;104(3):784-7. (PMID: 15069012) Leukemia. 2016 Jun;30(6):1246-54. (PMID: 26847027) Nature. 2012 Oct 4;490(7418):116-20. (PMID: 22885699) Nat Immunol. 2008 Jun;9(6):613-22. (PMID: 18469817) Blood Adv. 2020 Sep 8;4(17):4151-4164. (PMID: 32898245) EMBO J. 2002 May 1;21(9):2263-71. (PMID: 11980723) Semin Oncol. 2018 Oct;45(5-6):291-302. (PMID: 30360879) Dev Cell. 2003 Jan;4(1):119-29. (PMID: 12530968) Nature. 2015 Oct 22;526(7574):525-30. (PMID: 26466571) Mol Cell Proteomics. 2009 Dec;8(12):2796-808. (PMID: 19651622) Biochem J. 2000 Jul 15;349(Pt 2):629-34. (PMID: 10880363) Blood Adv. 2019 Jul 23;3(14):2118-2127. (PMID: 31300419) Am J Cancer Res. 2012;2(1):104-15. (PMID: 22206049) Cell Rep. 2020 Nov 17;33(7):108403. (PMID: 33207194) Semin Cancer Biol. 2018 Jun;50:132-141. (PMID: 28774833) Br J Haematol. 2008 Aug;142(4):538-50. (PMID: 18564361) Leukemia. 2015 Jan;29(1):115-25. (PMID: 24825182) Cancer Res. 2010 Jun 1;70(11):4709-18. (PMID: 20484037) Haematologica. 2015 Jan;100(1):55-61. (PMID: 25261097) Oncoimmunology. 2018 Jan 25;7(5):e1423183. (PMID: 29721381) J Exp Med. 2017 Apr 3;214(4):1181-1198. (PMID: 28351982) J Biol Chem. 2009 Oct 30;284(44):30695-707. (PMID: 19737929) Nat Cell Biol. 2006 Oct;8(10):1064-73. (PMID: 16964248) Leukemia. 2015 Aug;29(8):1623-31. (PMID: 25943180) J Biol Chem. 2002 Nov 22;277(47):45276-84. (PMID: 12228231) Int Immunol. 2009 Jul;21(7):831-42. (PMID: 19502585) Immunol Rev. 2015 Jan;263(1):192-209. (PMID: 25510278) J Immunol. 2004 Jul 15;173(2):1158-65. (PMID: 15240705) Cell. 2017 Oct 5;171(2):481-494.e15. (PMID: 28985567) Lancet Haematol. 2020 Jul;7(7):e511-e522. (PMID: 32589977) J Biol Chem. 2009 Jul 17;284(29):19349-60. (PMID: 19416966) Genes Dev. 2007 Nov 1;21(21):2775-87. (PMID: 17974917) Blood. 2018 Jun 28;131(26):2929-2942. (PMID: 29622548) Oncotarget. 2016 Oct 25;7(43):70000-70010. (PMID: 27661108) Oncotarget. 2017 Jan 10;8(2):2466-2476. (PMID: 27911272) Clin Cancer Res. 2019 Mar 1;25(5):1574-1587. (PMID: 30559170) J Biol Chem. 2019 Aug 30;294(35):13106-13116. (PMID: 31308176) Nat Med. 2012 Jun;18(6):892-901. (PMID: 22610277) Blood. 2016 Feb 11;127(6):739-48. (PMID: 26585955) Trends Genet. 2021 May;37(5):460-475. (PMID: 33303287) Nat Commun. 2015 Mar 10;6:6471. (PMID: 25753524) Int J Mol Med. 2003 Oct;12(4):503-8. (PMID: 12964026) Trends Pharmacol Sci. 2022 Dec;43(12):1070-1084. (PMID: 36280450) Oncogene. 1997 Jan 16;14(2):195-202. (PMID: 9010221) Cell. 1997 Dec 26;91(7):961-71. (PMID: 9428519) Biochim Biophys Acta. 2011 Nov;1813(11):1938-45. (PMID: 21708191) Blood. 2012 Apr 12;119(15):3503-11. (PMID: 22343918) EMBO Rep. 2004 Jan;5(1):60-5. (PMID: 14710188) Blood. 1993 Oct 1;82(7):2157-62. (PMID: 8104536) Nat Cell Biol. 2008 Feb;10(2):138-48. (PMID: 18204439) Cell. 2004 Feb 20;116(4):551-63. (PMID: 14980222) EMBO J. 2004 Dec 8;23(24):4802-12. (PMID: 15538382) Cell. 2000 Sep 1;102(5):565-75. (PMID: 11007475) J Cell Biol. 2002 Mar 4;156(5):817-28. (PMID: 11864996) Cell Death Dis. 2019 Dec 4;10(12):924. (PMID: 31801949) Genes Chromosomes Cancer. 1994 Oct;11(2):79-84. (PMID: 7529552) Immunity. 2015 Dec 15;43(6):1075-86. (PMID: 26620760) Blood. 2013 May 2;121(18):3666-74. (PMID: 23460611) Immunity. 2018 Feb 20;48(2):313-326.e5. (PMID: 29396161) Haematologica. 2022 Mar 01;107(3):690-701. (PMID: 33792219) Nat Immunol. 2012 Nov;13(11):1083-91. (PMID: 23001145) Leuk Lymphoma. 2008 Mar;49(3):477-87. (PMID: 18297524) Cancer Discov. 2018 Feb;8(2):174-183. (PMID: 29247016) Cell Rep. 2020 May 12;31(6):107621. (PMID: 32402289) Adv Exp Med Biol. 2020;1254:23-36. (PMID: 32323266) Oncogene. 2007 Nov 1;26(50):7081-91. (PMID: 17496928) J Exp Med. 2021 Apr 5;218(4):. (PMID: 33332554) Br J Cancer. 2013 Jul 23;109(2):387-94. (PMID: 23828518) Cancer Res. 2011 May 1;71(9):3257-67. (PMID: 21505104) Clin Cancer Res. 2016 May 1;22(9):2290-300. (PMID: 26647218) |
| معلومات مُعتمدة: | MR/X008169/1 United Kingdom MRC_ Medical Research Council |
| فهرسة مساهمة: | Keywords: B cell malignancy; BCR signalling; FOXO transcription factor; PI3K/AKT; leukemia; lymphoma; tumor suppressor |
| المشرفين على المادة: | 0 (Forkhead Transcription Factors) 0 (FOXO6 protein, human) |
| تواريخ الأحداث: | Date Created: 20230605 Date Completed: 20230607 Latest Revision: 20240306 |
| رمز التحديث: | 20240306 |
| مُعرف محوري في PubMed: | PMC10233034 |
| DOI: | 10.3389/fimmu.2023.1179101 |
| PMID: | 37275916 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1179101 |